Table 3 Relationship between 13q deletion rates and treatment status, β2 microglobulin levels and RAI stages
From: Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
13q deletion rate | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
< 80% n (%) | > 80% n (%) | Total | p value | 70% n (%) | > 70% n (%) | Total | p value | < 60% n (%) | > 60% n (%) | Total | p value | |
Treatment | ||||||||||||
Positive | 13 (56) | 10 (44) | 23 | p < 0.05 | 14 (61) | 9 (39) | 23 | p > 0.05 | 11 (48) | 12 (52) | 23 | p > 0.05 |
Negative | 35 (85) | 6 (15) | 41 | 29 (71) | 12 (29) | 41 | 25 (61) | 16 (39) | 41 | |||
Total | 48 (75) | 16 (25) | 64 | 43 (67) | 21 (33) | 64 | 36 (56) | 28 (44) | 64 | |||
β2 microglobuline level | ||||||||||||
<3.5 mg/dl | 14 (78) | 4 (22) | 18 | p > 0.05 | 14 (78) | 4 (22) | 18 | p > 0.05 | 12 (67) | 6 (33) | 18 | p > 0.05 |
>3.5 mg/dl | 12 (80) | 3 (20) | 15 | 11 (73) | 4 (27) | 15 | 10 (67) | 5 (33) | 15 | |||
Total | 26 (79) | 7 (21) | 33 | 25 (76) | 8 (24) | 33 | 22 (67) | 11 (33) | 33 | |||
RAI stage | ||||||||||||
0, 1, 2 | 37 (80) | 9 (20) | 46 | p > 0.05 | 31 (67) | 15 (33) | 46 | p > 0.05 | 28 (61) | 18 (39) | 46 | p > 0.05 |
3, 4 | 8 (57) | 6 (43) | 14 | 9 (64) | 5 (36) | 14 | 6 (43) | 8 (57) | 14 | |||
Total | 45 (75) | 15 (25) | 60 | 40 (67) | 20 (33) | 60 | 34 (57) | 26 (43) | 60 | |||